Literature DB >> 21905996

Comorbidity of schizophrenia and adult attention-deficit hyperactivity disorder.

Rossen Donev1, Daniel Gantert, Khaled Alawam, Ann Edworthy, Frank Hässler, Andreas Meyer-Lindenberg, Harald Dressing, Johannes Thome.   

Abstract

OBJECTIVES: Adult ADHD is characterised by a plethora of comorbid conditions. However, the comorbidity of schizophrenia and ADHD does not seem to be a typical feature and is therefore under-researched.
OBJECTIVE: To identify adult patients with schizophrenia and comorbid ADHD and compare their symptomatology with schizophrenic patients without ADHD.
METHOD: Performance in specific neuropsychological tests (set shifting, selective and sustained attention, cognitive performance, and speed of information processing) was determined. Additionally, important demographic data and information about the patients' history such as the number of suicide attempts were gathered. Twenty-seven patients were involved in this study (14 male and 13 female). Fifteen patients were diagnosed with schizophrenia/no ADHD and twelve had both schizophrenia/ADHD.
RESULTS: We report here an increase in suicidal behaviour of patients with both schizophrenia and ADHD compared to schizophrenia only. A significant underperformance of the patients with ADHD comorbidity compared to patients with schizophrenia only was also determined.
CONCLUSIONS: The increased suicidal behaviour in patients with schizophrenia and ADHD suggests the need of further studies on mood regulation and suicidal ideations in these patients.

Entities:  

Mesh:

Year:  2011        PMID: 21905996     DOI: 10.3109/15622975.2011.599212

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  8 in total

1.  Detecting and treating adult attention deficit hyperactivity disorder in a patient with schizophrenia.

Authors:  Julia Huemer; Ingrid Sibitz
Journal:  Neuropsychiatr       Date:  2014-05-20

2.  Attention-deficit/hyperactivity disorder in youth with psychosis spectrum symptoms.

Authors:  Victoria Fox; Julia M Sheffield; Neil D Woodward
Journal:  Schizophr Res       Date:  2021-09-13       Impact factor: 4.939

3.  Symptom Overlap and Screening for Symptoms of Attention-Deficit/Hyperactivity Disorder and Psychosis Risk in Help-Seeking Psychiatric Patients.

Authors:  Salvatore Corbisiero; Anita Riecher-Rössler; Jacqueline Buchli-Kammermann; Rolf-Dieter Stieglitz
Journal:  Front Psychiatry       Date:  2017-10-30       Impact factor: 4.157

4.  Attention-deficit/hyperactivity disorder and suicide: A systematic review.

Authors:  Judit Balazs; Agnes Kereszteny
Journal:  World J Psychiatry       Date:  2017-03-22

5.  Gabrb3 endothelial cell-specific knockout mice display abnormal blood flow, hypertension, and behavioral dysfunction.

Authors:  Anass Agrud; Sivan Subburaju; Pranay Goel; Jun Ren; Ashwin Srinivasan Kumar; Barbara J Caldarone; Wangde Dai; Jesus Chavez; Dai Fukumura; Rakesh K Jain; Robert A Kloner; Anju Vasudevan
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

6.  Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia.

Authors:  Fernanda F Peres; Mariana C Diana; Raquel Levin; Mayra A Suiama; Valéria Almeida; Ana M Vendramini; Camila M Santos; Antônio W Zuardi; Jaime E C Hallak; José A Crippa; Vanessa C Abílio
Journal:  Front Pharmacol       Date:  2018-08-21       Impact factor: 5.810

7.  Gabrb2-knockout mice displayed schizophrenia-like and comorbid phenotypes with interneuron-astrocyte-microglia dysregulation.

Authors:  Rigil K Yeung; Zheng-Hua Xiang; Shui-Ying Tsang; Rui Li; Timothy Y C Ho; Qi Li; Chok-King Hui; Pak-Chung Sham; Ming-Qi Qiao; Hong Xue
Journal:  Transl Psychiatry       Date:  2018-07-17       Impact factor: 6.222

8.  Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia.

Authors:  I Arican; N Bass; K Neelam; K Wolfe; A McQuillin; G Giaroli
Journal:  Acta Psychiatr Scand       Date:  2018-08-13       Impact factor: 6.392

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.